Could a diabetes drug boost brain recovery after stroke?

NCT ID NCT07511543

Not yet recruiting Disease control Sponsor: Population Health Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This pilot study tests whether giving semaglutide (Ozempic) to 100 stroke patients who had a clot-removal procedure can improve recovery. Patients are randomly assigned to receive weekly injections for 12 weeks or no drug. The main goal is to see if a larger, definitive trial is possible by tracking recruitment, adherence, and retention. If successful, it could lead to a bigger study aiming to reduce death and long-term disability after stroke.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Ozempic), a weekly injection under the skin
What this could lead to: If this pilot shows it's feasible, it could pave the way for a larger study testing whether semaglutide reduces death and disability after a severe stroke.
What could go wrong: This is a very early, small pilot study (100 people) focused on feasibility, not on proving the drug works. Even if feasible, semaglutide may not improve stroke recovery and could have side effects like nausea or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO ANTERIOR CIRCULATION LARGE VESSEL OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.